-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-02-18
Values as of: 2025-02-18
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 31/01/2006
Primary Benchmark: S&P Biotechnology Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
XLV | Health Care Select Sector SPDR.. | 0.13 % |
+1.88 (+1.30%) |
USD 37.71B |
FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
+0.91 (+1.33%) |
USD 2.77B |
FXH | First Trust Health Care AlphaD.. | 0.63 % |
+1.38 (+1.28%) |
USD 1.05B |
XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+0.49 (+0.53%) |
USD 0.20B |
IDNA | iShares Genomics Immunology an.. | 0.00 % |
-0.01 (-0.04%) |
USD 0.12B |
SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+0.14 (+0.43%) |
USD 0.09B |
XHS | SPDR® S&P Health Care Service.. | 0.35 % |
+1.53 (+1.51%) |
USD 0.08B |
HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.32 (+1.06%) |
USD 0.05B |
BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
+0.39 (+0.61%) |
USD 0.02B |
BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
+0.12 (+0.54%) |
USD 6.89M |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
MATH | Metalpha Technology Holdi.. | 0.00 % | 1.35 % |
-0.30 (0%) |
USD 0.10B |
INAV | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 1.41% | 14% | F | 41% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 1.41% | 14% | F | 40% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -1.14% | 24% | F | 28% | F | ||
Dividend Return | 0.14% | 19% | F | 1% | F | ||
Total Return | -1.00% | 19% | F | 21% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -6.63% | 19% | F | 41% | F | ||
Dividend Return | 0.48% | 26% | F | 2% | F | ||
Total Return | -6.15% | 19% | F | 22% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -3.21% | 14% | F | 18% | F | ||
Dividend Return | -3.14% | 14% | F | 11% | F | ||
Total Return | 0.07% | 21% | F | 3% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 29.79% | 19% | F | 36% | F | ||
Risk Adjusted Return | -10.53% | 14% | F | 15% | F | ||
Market Capitalization | 3.15B | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.